IBDEI34B ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,49800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49800,1,3,0)
 ;;=3^Heart Failure,Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,49800,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,49800,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,49801,0)
 ;;=I50.42^^193^2482^36
 ;;^UTILITY(U,$J,358.3,49801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49801,1,3,0)
 ;;=3^Heart Failure,Systolic & Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,49801,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,49801,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,49802,0)
 ;;=I13.0^^193^2482^30
 ;;^UTILITY(U,$J,358.3,49802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49802,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,49802,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,49802,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,49803,0)
 ;;=I13.2^^193^2482^31
 ;;^UTILITY(U,$J,358.3,49803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49803,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,49803,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,49803,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,49804,0)
 ;;=I13.10^^193^2482^32
 ;;^UTILITY(U,$J,358.3,49804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49804,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,49804,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,49804,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,49805,0)
 ;;=I13.11^^193^2482^33
 ;;^UTILITY(U,$J,358.3,49805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49805,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,49805,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,49805,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,49806,0)
 ;;=E03.9^^193^2482^43
 ;;^UTILITY(U,$J,358.3,49806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49806,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,49806,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,49806,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,49807,0)
 ;;=M54.5^^193^2482^46
 ;;^UTILITY(U,$J,358.3,49807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49807,1,3,0)
 ;;=3^Low Back Pain
 ;;^UTILITY(U,$J,358.3,49807,1,4,0)
 ;;=4^M54.5
 ;;^UTILITY(U,$J,358.3,49807,2)
 ;;=^5012311
 ;;^UTILITY(U,$J,358.3,49808,0)
 ;;=C61.^^193^2482^47
 ;;^UTILITY(U,$J,358.3,49808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49808,1,3,0)
 ;;=3^Malig Neopl Prostate
 ;;^UTILITY(U,$J,358.3,49808,1,4,0)
 ;;=4^C61.
 ;;^UTILITY(U,$J,358.3,49808,2)
 ;;=^267239
 ;;^UTILITY(U,$J,358.3,49809,0)
 ;;=F11.20^^193^2482^53
 ;;^UTILITY(U,$J,358.3,49809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49809,1,3,0)
 ;;=3^Opioid Dependence,Uncomplicated
 ;;^UTILITY(U,$J,358.3,49809,1,4,0)
 ;;=4^F11.20
 ;;^UTILITY(U,$J,358.3,49809,2)
 ;;=^5003127
 ;;^UTILITY(U,$J,358.3,49810,0)
 ;;=M19.90^^193^2482^54
 ;;^UTILITY(U,$J,358.3,49810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49810,1,3,0)
 ;;=3^Osteoarthritis,Unspec
 ;;^UTILITY(U,$J,358.3,49810,1,4,0)
 ;;=4^M19.90
 ;;^UTILITY(U,$J,358.3,49810,2)
 ;;=^5010853
 ;;^UTILITY(U,$J,358.3,49811,0)
 ;;=M85.80^^193^2482^55
 ;;^UTILITY(U,$J,358.3,49811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49811,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,49811,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,49811,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,49812,0)
 ;;=M81.0^^193^2482^56
 ;;^UTILITY(U,$J,358.3,49812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49812,1,3,0)
 ;;=3^Osteoporosis,Age-Related w/o Fx
